REGENXBIO announced positive topline results from its pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, a gene therapy for Duchenne muscular dystrophy, achieving its primary endpoint with high statistical significance and showing a correlation between microdystrophin expression and functional improvement. The therapy was well-tolerated with a favorable safety profile. The company plans potential accelerated approval in 2027 and is progressing other gene therapy programs for retinal and neurodegenerative diseases. Financially, REGENXBIO reported a net loss for Q1 2026 but maintains a cash runway into early 2027. A webcast is scheduled to discuss these results and Q1 updates.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
